RxDoctor Payments Data

Howard Nizar, MD

Internal Medicine · Bakersfield, CANPI 1326124603

Payments from drug & device makers

$1,261in general payments, 2019–2025

Across 66 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$199
  • AstraZeneca$146
  • GSK$115
  • Lilly USA, LLC$114
  • Johnson & Johnson$101
  • Dexcom, Inc.$81
  • plus $505 from 14 others

What the payments were for

  • Food & beverage$1,24399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,261 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$204,526
Medicare patients
332
Services billed
1,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide198$221,363
JardianceEmpagliflozin89$94,419
JanuviaSitagliptin Phosphate42$56,464
RybelsusSemaglutide46$53,343
EliquisApixaban53$50,457
MounjaroTirzepatide42$44,540
FarxigaDapagliflozin Propanediol42$34,604
XareltoRivaroxaban40$32,837
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$26,618
TrulicityDulaglutide25$23,792
LinzessLinaclotide23$11,967
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$10,159
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$7,895
EntrestoSacubitril/Valsartan11$7,834
Atorvastatin Calcium759$6,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$46$274,706244 claims
Boehringer IngelheimJardiance$199$94,41989 claims
Lilly USA, LLCMounjaro, Trulicity$114$68,33367 claims
MerckJanuvia$16$56,46442 claims
PfizerEliquis$71$50,45753 claims
AstraZenecaFarxiga$146$34,60442 claims
GSKTrelegy Ellipta, Anoro Ellipta$115$34,51252 claims
Johnson & JohnsonXarelto$101$32,83740 claims
AbbVieLinzess, Synthroid$55$15,52170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →